Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Sjogren A Belimumab"

20:57 EDT 29th July 2014 | BioPortfolio

Original Source: Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by an increase in BAFF (BLyS) levels and a resulting B cell hyperactivity. B cells are involved in the pathogenesis of SS in both systemic and glandular features, and B cell downregulation may lead to a decrease of disease activity. Moreover, pathogenesis of SS is closed to that of Systemic lupus erythematosus, where Belimumab has been proven to be effective.

Matching Channels


Matching News

Pregnancy Possible in Lupus Patients Taking Belimumab

Successful live births are possible in women with lupus who conceive while taking belimumab, new research shows. Medscape Medical News

Rituximab Disappoints in Sjogren Syndrome

Medscape Medical News

For Moderate to Severe Systemic Lupus Erythematosus, Epratuzumab Has the Potential to Offer Improvements over IV Belimumab in Health-Related Quality of Life and Time to Response

BURLINGTON, Mass., April 28, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and EU5 rheumatologists agree that new therapies for the treatment of moderate to severe system...

Pipeline innovation bodes well for systemic lupus erythematosus market

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s Benlysta (belimumab) and off-label Rituxan (rituximab), new emerging entrants, which appe...

The BAFF/APRIL system in SLE pathogenesis

In this article the authors review the 'BAFF/APRIL system', a complex of the cytokines BAFF and APRIL, their receptors and signalling pathways. The efficacy of belimumab, an anti-BAFF biologic agent u...

Aldeyra raises $12 million in IPO

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) raised $12 million in an IPO through a bumped-up number of shares below its proposed price range. The company sold 1.5 million shares at $8, which values Aldeyr...

Aldeyra drops proposed IPO shares

Aldeyra Therapeutics Inc. (Burlington, Mass.) lowered to 1.2 million the number of shares it plans to sell at $10-$12 in an IPO on NASDAQ. At the $11 midpoint, Aldeyra (formerly Aldexa Therapeutics In...

Aldeyra sets IPO range

Aldeyra Therapeutics Inc. (Burlington, Mass.) said it plans to sell 2 million shares at $10-$12 in an IPO on NASDAQ underwritten by Aegis Capital. At the $11 midpoint, Aldeyra (formerly Aldexa Therape...

Matching PubMed Articles

Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.

This case report describes two female lupus patients who both received biological treatment with tocilizumab and with belimumab. The disease course was remarkably similar in both cases. Tocilizumab re...

A23: favorable response to belimumab in childhood-onset systemic lupus erythematosus.

Belimumab (Benlysta) is a human monoclonal antibody inhibiting soluble B-lymphocyte stimulator that was approved by the Food and Drug Administration in 2011 for treatment of active, autoantibody-posit...


Case of Sjogren syndrome.

The classification criteria for Sjogren syndrome: issues for their improvement from the study of a large Italian cohort of patients.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement